from web site
Clinical Next-Generation Sequencing (NSG) Testing Market Size And Forecast by 2031
Technological advancements in the clinical next-generation sequencing (NSG) testing coupled with rising research and development proficiencies are fostering the market growth. Data Bridge Market Research analyses that the clinical next-generation sequencing (NSG) testing market will exhibit a CAGR of around 27.25% for the forecast period of 2021-2028.. Clinical Next-Generation Sequencing (NSG) Testing Market report provides a holistic evaluation of the market. The report offers comprehensive analysis of Size, Share, Scope, Demand, Growth, Value, Opportunities, Industry Statistics, Industry Trends, Industry Share, Revenue Analysis, Revenue Forecast, Future Scope, Challenges, Growth Drivers, leaders, graph, insights, Research Report, companies, overview, outlook and factors that are playing a substantial role in the market.
Global Clinical Next-Generation Sequencing (NSG) Testing Market, By Technology (Sequencing By Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-time Sequencing, Nano Pore Sequencing and Other Sequencing Technologies), Application (Diagnostics, Drug Discovery, Agricultural and Animal Research and Other Applications), End User (Academic Institutes and Research Centres, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Other End Users), Service (Human Genome Sequencing, Single Cell Sequencing, Microbial Genome-based Sequencing, Gene Regulation Services, Animal and Plant Sequencing and Other Sequencing Services), Workflow (Pre-Sequencing, Sequencing and Data Analysis), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-clinical-next-generation-sequencing-nsg-testing-market
Which are the top companies operating in the Clinical Next-Generation Sequencing (NSG) Testing Market?
The “Global Clinical Next-Generation Sequencing (NSG) Testing Market ”study report will provide a valuable insight with an emphasis on the global market. The report profiles noticeable organizations working in the water purifier showcase and the triumphant methodologies received by them. It likewise reveals insights about the share held by each organization and their contribution to the Clinical Next-Generation Sequencing (NSG) Testing Market extension. This Clinical Next-Generation Sequencing (NSG) Testing Market report provides the information of the Top 10 Companies in Clinical Next-Generation Sequencing (NSG) Testing Market in the market their business strategy, financial situation etc.
**Segments**
- By Test Type: Targeted Gene Panels & High-Throughput Exome Sequencing, RNA Sequencing, Whole-Exome Sequencing, Whole-Genome Sequencing.
- By Disease Indication: Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Blood Cancer, Prostate Cancer, Others), Genetic Disorders, Infectious Diseases, Cardiovascular Diseases.
- By Technology: Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Nanopore Sequencing, Single-Molecule Real-Time (SMRT) Sequencing.
- By Application: Drug Discovery, Diagnostics, Personalized Medicine, Agricultural & Animal Research.
The clinical Next-Generation Sequencing (NSG) testing market is expected to witness significant growth between 2020 and 2028. Factors such as the rising prevalence of cancer and genetic disorders, technological advancements in sequencing techniques, growing investments in genomics research, and increasing applications of NGS in personalized medicine are driving the market's growth. The market is segmented based on test type, disease indication, technology, and application.
In terms of test type, the market is divided into targeted gene panels & high-throughput exome sequencing, RNA sequencing, whole-exome sequencing, and whole-genome sequencing. Targeted gene panels & high-throughput exome sequencing are widely used in oncology for identifying genetic mutations associated with different types of cancer. RNA sequencing is essential for studying gene expression patterns, while whole-exome sequencing and whole-genome sequencing provide a comprehensive analysis of an individual's genetic makeup.
Based on disease indication, the market is categorized into oncology, genetic disorders, infectious diseases, and cardiovascular diseases. Oncology holds a significant market share due to the increased adoption of NGS in cancer diagnostics and treatment decision-making. Genetic disorders and infectious diseases segments are also expected to grow rapidly, driven by the need for accurate and rapid genetic testing.
With respect to technology, the market is segmented into sequencing by synthesisThe Next-Generation Sequencing (NGS) market is witnessing a paradigm shift with the emergence of various sequencing technologies offering enhanced capabilities and efficiencies. Sequencing by Synthesis (SBS) technology is the most commonly used method, known for its high accuracy and cost-effectiveness. However, Ion Semiconductor Sequencing is gaining traction due to its ability to directly measure hydrogen ions released during DNA synthesis, offering faster run times. Nanopore Sequencing, known for its ability to sequence long reads in real-time, is increasingly being utilized in applications requiring rapid results, such as infectious disease surveillance. Single-Molecule Real-Time (SMRT) Sequencing, offered by Pacific Biosciences, enables long-read sequencing with high accuracy, making it suitable for resolving complex genomic regions and structural variations.
The application of NGS technology is broadening across various sectors, with Drug Discovery, Diagnostics, Personalized Medicine, and Agricultural & Animal Research being key segments. In Drug Discovery, NGS is revolutionizing the identification of novel drug targets, biomarkers, and pharmacogenomic markers, leading to the development of personalized therapies. In Diagnostics, NGS is enabling precise and swift diagnosis of genetic disorders, infectious diseases, and cancer, thereby improving patient outcomes. The field of Personalized Medicine is leveraging NGS to tailor medical decisions and treatments according to an individual's genetic makeup, optimizing therapeutic efficacy. Moreover, in Agricultural & Animal Research, NGS is assisting in enhancing crop yields, breeding disease-resistant livestock, and preserving biodiversity through genomics-assisted breeding programs.
The convergence of advancements in NGS technologies, expansion of application areas, and the growing demand for precision medicine is propelling the market forward. Additionally, collaborations between academic research institutions, pharmaceutical companies, and sequencing technology providers are fostering innovation and driving the adoption of NGS in clinical settings. The increasing focus on population genomics initiatives and the integration of artificial intelligence (AI) and machine learning algorithms for data analysis are further fueling market growth. As**Market Players:**
3billion, Inc., 10x Genomics., 23andMe, Inc., Adaptive Biotechnologies., Admera Health, Agilent Technologies, Inc., ALCEN, Almac Group, AMARANTUS BIOSCIENCE HOLDINGS, INC., Ambry Genetics., Aperiomics, Inc., ARUP Laboratories., ASURAGEN, INC., Athena Diagnostics, Inc., Atreca, Inc., Base4, Baylor Genetics, BD, Berry Gene, BGI, Bioarray S.L, Biodesix., Boreal Genomics Inc., and Cambridge Epigenetix Limited among other domestic and global players.
The clinical Next-Generation Sequencing (NGS) testing market is experiencing notable growth opportunities fueled by key drivers such as the increasing prevalence of cancer and genetic disorders, advancements in sequencing technologies, rising investments in genomics research, and expanding applications of NGS in personalized medicine. The market segmentation based on test type, disease indication, technology, and application allows for a comprehensive analysis of the landscape.
In terms of test types, targeted gene panels & high-throughput exome sequencing, RNA sequencing, whole-exome sequencing, and whole-genome sequencing cater to different needs in the clinical NGS space. These tests play crucial roles in oncology for mutation identification, gene expression analysis, and comprehensive genetic profiling. The disease indication segment covers oncology, genetic disorders, infectious diseases, and cardiovascular diseases, highlighting the broad spectrum of
Data Bridge Market Research typically follows a comprehensive research methodology for analyzing and reporting on market trends, including the Clinical Next-Generation Sequencing (NSG) Testing Market. The research methodology generally involves the following steps:
This structured approach ensures that the research conducted by Data Bridge Market Research is thorough, accurate, and provides actionable insights for stakeholders in the Clinical Next-Generation Sequencing (NSG) Testing Market.
Browse More Reports:
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) Treatment Market
Paraganglioma Treatment Market
Crigler–Najjar Syndrome Market
Packaging Coatings Resins Market
Organic Ice-Cream Market
4-Dimensional Printing in Healthcare Market
Naphthenic Base Oil Market
Residues and Contamination Testing Market
Research Antibodies Market
Lactose Market
Breakfast Cereals Market
Computer Numerical Control Machines Market
Ground Penetrating Radar Market
Floor Coatings Market
Resol Resin Market
Fuel Dyes Market
Latin America Cochlear Implants Market
Data Bridge Market Research:
Today's trends are a great way to predict future events!
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC: +653 1251 975